Bagsværd, Denmark, 22 June– Today, The New England Journal of Medicine published results from Novo Nordisk’ s phase 3 REDEFINE 1 trial evaluating the efficacy and safety of investigational ...

The collaboration, set to begin on 1 July, will see Novo Nordisk team up with the telehealth company to offer Wegovy to customers. WeightWatchers will work with CenterWell Pharmacy to dispense, manage ...

In Novo Nordisk A/S’s home country of Denmark, the popularity of weight-loss drugs is fueling economic growth, but local retailers are now warning they will take a hit as food consumption declines.

Weight-loss patients voice concerns as CVS Caremark drops Zepbound coverage for Wegovy, though exceptions may exist for those ...

The partnership forged by Novo Nordisk (NVO) and Hims & Hers (HIMS) in April appeared to bring together two giant brands in the growing weight-loss market. It's why the sudden fallout less than ...

Novo Nordisk sees 65% obesity drug sales growth, forecasts $8.14–$9.59B FY25 free cash flow. Click here to read an analysis ...

Novo Nordisk ( NVO 1.34%) and Regeneron Pharmaceuticals ( REGN -0.27%), two leading drugmakers, have underperformed for most ...

Current health news covers Roche's Alzheimer's drug research, UnitedHealth's leadership hopes, Nordic Capital's ...

Eli Lilly and Novo Nordisk are currently the only drugmakers with FDA approved weight-loss medicines on the U.S. market.

Novo Nordisk's best-known drug, Wegovy, targets a GPCR called GLP-1. Eli Lilly 's popular weight-loss drug Zepbound targets both GLP-1 and another GPCR called GIP.

Key Points Pfizer and Novo Nordisk have underperformed the market over the past year.But both should remain major players in ...